Rosiglitazone Prior Authorization Safety Policy: A Cohort Study

Abstract

This PA, intended to reduce known cardiovascular event risks among health plan members with type 2 diabetes, was associated with a significant reduction in concurrent use of rosiglitazone with nitrates or insulin.